His main research concerns Surgery, Chemotherapy, Internal medicine, Oncology and Sarcoma. The various areas that Michael P. Link examines in his Surgery study include Osteosarcoma and Lymphoma. His studies deal with areas such as Regimen, Primary tumor and Radiation therapy as well as Chemotherapy.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. As a part of the same scientific study, Michael P. Link usually deals with the Oncology, concentrating on Etoposide and frequently concerns with Melphalan, Univariate analysis and Rhabdomyosarcoma. His work in the fields of Sarcoma, such as Ewing's sarcoma, Primitive neuroectodermal tumor and Neuroectodermal tumor, intersects with other areas such as Subset Analysis.
His primary areas of study are Internal medicine, Surgery, Oncology, Chemotherapy and Pathology. His studies link Gastroenterology with Internal medicine. Michael P. Link combines subjects such as Osteosarcoma, Clinical trial, Rhabdomyosarcoma and Lymphoma with his study of Surgery.
His research in Oncology focuses on subjects like Sarcoma, which are connected to Cancer. Michael P. Link interconnects Regimen, Methotrexate and Radiation therapy in the investigation of issues within Chemotherapy. The Pathology study combines topics in areas such as Immunophenotyping and Cytogenetics.
Michael P. Link spends much of his time researching Internal medicine, Oncology, Surgery, Young adult and Lymphoma. Michael P. Link combines Internal medicine and MISMATCH REPAIR DEFICIENCY in his research. His Oncology research incorporates themes from Cancer, Survival benefit, Vincristine and Brentuximab vedotin, Hodgkin lymphoma.
In general Surgery study, his work on Chemotherapy, Autologous transplantation and Cyclophosphamide often relates to the realm of Watchful waiting, thereby connecting several areas of interest. His Chemotherapy research incorporates elements of Asymptomatic, Radiation therapy and Prednisone. Michael P. Link works mostly in the field of Pathology, limiting it down to concerns involving Follicular dendritic cells and, occasionally, Leukemia.
Michael P. Link mainly investigates Young adult, Internal medicine, Psychosocial, Oncology and Cancer. Michael P. Link works mostly in the field of Young adult, limiting it down to topics relating to Fertility preservation and, in certain cases, Cause of death, Family medicine, Adolescent medicine and Pregnancy. His research on Internal medicine often connects related topics like Surgery.
His Surgery research integrates issues from Magnetic resonance imaging and Ferumoxytol. Michael P. Link has included themes like Fertility, Regimen, Cyclophosphamide and Lymphoma, Hodgkin lymphoma in his Oncology study. The concepts of his Cancer study are interwoven with issues in Childhood leukemia and Pediatrics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
M P Link;A M Goorin;A W Miser;A A Green.
The New England Journal of Medicine (1986)
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link.
The New England Journal of Medicine (2003)
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
M Smith;D Arthur;B Camitta;A J Carroll.
Journal of Clinical Oncology (1996)
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey.
Journal of Clinical Oncology (2008)
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman.
Journal of Clinical Oncology (2005)
National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002.
Patrick Dl;Ferketich Sl;Frame Ps;Harris Jj.
Journal of The National Cancer Institute Monographs (2004)
Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV
John C. Breneman;Elizabeth Lyden;Alberto S. Pappo;Michael P. Link.
Journal of Clinical Oncology (2003)
Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651
Allen M. Goorin;Douglas J. Schwartzentruber;Meenakshi Devidas;Mark C. Gebhardt.
Journal of Clinical Oncology (2003)
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
M D Amylon;J Shuster;J Pullen;C Berard.
Attitudes and Practices Among Pediatric Oncologists Regarding End-of-Life Care: Results of the 1998 American Society of Clinical Oncology Survey
Joanne M. Hilden;Ezekiel J. Emanuel;Diane L. Fairclough;Michael P. Link.
Journal of Clinical Oncology (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: